Since hitting a low of $19.65 on April 5, shares of Commercial Metals Company (NYSE: CMC) have gained about 23 percent, prompting Bank of America Merrill Lynch to revisit its rating on the equity.
Analyst Timna Tanners downgraded Commercial Metals from Neutral to Underperform and lowered the price target from $24 to $23.
Commercial Metals' valuation already reflects its much better-than-normal earnings power and its proposed plan to acquire four Gerdau U.S. rebar mills that's scheduled to close by the end of the year, Tanners said in a Tuesday note. (See the analyst's track record here.)
On the downside, the analyst projects potential antitrust challenges to the Gerdau deal due to excess concentration, as imports now face a 25-percent Section 232 tariff, Tanners said.
Taking into account the weakness of the Turkish lira — which is down 24 percent year-to-date — the price of imported rebar has dropped, resulting in a $125/ton discount to U.S. prices even after tariffs were applied, the analyst said.
BofA expects U.S. rebar imports to rebound in Q4 after a summer dip, along with additional volume from Steel Dynamics, Inc. (NASDAQ: STLD).
The U.S. rebar market was oversupplied before the Trump administration's tariffs, Tanners said. Utilization remains below 80 percent, indicating limited pricing power, the analyst said.
"In recent midquarter updates on peers NUE and STLD we revisit valuation to use 'normal' multiples on conservative benchmark hot rolled coil and still find upside."
BofA prefers Nucor Corporation (NYSE: NUE) and Steel Dynamics to Commercial Metals.
The Price Action
Commercial Metals shares were down 3.86 percent at $23.15 at the time of publication Tuesday afternoon.
Goldman Sachs Initiates On A Slew Of Metal and Mining Stocks
KeyBanc Urges 'Selective Bias' On Carbon Steel Stocks
Latest Ratings for CMC
|Jun 2018||Bank of America||Downgrades||Neutral||Underperform|
View More Analyst Ratings for CMC
View the Latest Analyst Ratings
See more from Benzinga
- Citi: F5 Networks Shares Fully Valued After Recent Rally
- Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study
- Any Permian Fall-Off For Helmerich & Payne Is Shallow, Jefferies Says In Upgrade
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.